Informative. Hinted that sales were down due to seasonality...more color on today's cc.Looking at sales of $25-30 million in the first 5 months in US. They see no need to partner with anyone; market too small and they have the right people to market this product successfully.No J code for first year. Will provide reimbursement assistance for and subsidize co-payments. In US 575,000 with DME grows at 115000/ year. With Europe the total DME pop grows to 835000. They said "a $2 billion opportunity". But they also said that they could capture 14% of the DME patients (I think thats what they said) Not sure which populations they used for the math because I didn't see the graphs. My math shows that after they satisfy the backlog, the future market opp slows to 115k new DME patients per year. So 14% of that is 16,100 patients for steroid treatments. Times approx $8.5K per injection = ~$136.9 million in sales/year. Does anyone see this differently?